In a community based study in Japan, researchers investigated if low
serum amylase is linked with an increased risk of metabolic diseases such as
diabetes and Metabolic Syndrome (Met S).
In 2,425 asymptomatic subjects (aged 30 - 80)
serum amylase, Metabolic Syndrome (Adult
Treatment Panel III criteria), cardiac risk factors, and diabetes were
examined. The subjects were studied over a period of 5 years and had the first medical checkups at the start and
again between April 2009-March 2010.
Dr. Kei Nakajima of Josai
University, Japan and colleagues observed during the study that except for the age and estimated
glomerular filtration rate (eGFR), clinical
variables shifted favorably with inceasing serum amylase levels. Plasma glucose levels at
one and two hours during oral glucose tolerance test increased significantly
with decreasing serum amylase levels
. Compared with highest quartile of serum amylase, multiple
logistic analyses depicted that the lowest quartile was associated with greater
risk for MetS and diabetes after adjustment for confounding factors. For
subjects who underwent checkups 5 years previously (n = 571), lower amylase levels at the were seen to be associated with greater number of metabolic abnormalities at the recent checkup. The
variation over time in serum amylase levels in people with low serum amylase at
the previous checkup was less and remained unaffected by kidney dysfunction.
Dr. Nakajima concluded the study with a note saying, "Our results indicate that lower
serum amylase levels are associated with increased risk of metabolic
abnormalities, diabetes, Metabolic Syndrome.
The study results do suggest a pancreatic exocrine-endocrine relationship in clinical conditions."